Evaluation by a Vineland II Scale of Long-term Development of Children with Pyridoxine Dependent Epilepsy

Last updated: March 18, 2025
Sponsor: University Hospital, Angers
Overall Status: Active - Recruiting

Phase

N/A

Condition

Epilepsy

Treatment

VINELAND II

Clinical Study ID

NCT06054347
49RC23_0181
  • Ages > 3
  • All Genders

Study Summary

This study aims to evaluate with the VINELAND II scale the long-term neurocognitive development of children above age 3 years with pyridoxine dependent epilepsy related to antiquitine deficiency.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age above 3 years old

  • Pyridoxine dependent epilepsy genetic diagnosis (mutation in ALDH7A1 gene)

  • No objection of the patient or his legal representatives.

Exclusion

Exclusion Criteria:

  • Poor understanding of French language.

Study Design

Total Participants: 30
Treatment Group(s): 1
Primary Treatment: VINELAND II
Phase:
Study Start date:
December 29, 2023
Estimated Completion Date:
September 30, 2025

Study Description

Pyridoxine dependent epilepsy related to antiquitine deficiency is a rare and severe genetic epilepsy that usually starts within the first month of life. The treatment is based on high dose of Vitamin B6 (Pyridoxine) which is usually highly effective to control the seizures. However, most patients show impaired neurodevelopment.

Ten years ago, international recommendations have changed and a lysine restricted diet was added as an adjunct therapy with the hope to improve neurodevelopment.

Very few studies have evaluated the cognitive development of these patients in a standardized way, and these studies evaluate very few patients.

It seems therefore essential to study in a standardized way the neurocognitive development of these patients in order to evaluate the impact of the care.

The VINELAND adaptative behaviour scale II has been chosen because it can evaluate a patient whatever the age or the intellectual abilities through a semi-structured questionnaire completed with the parents, and gives a wide view of the neurocognitive development and everyday life autonomy of the patients.

Connect with a study center

  • CHU Angers

    Angers, 49100
    France

    Active - Recruiting

  • Centre Hospitalier Universitaire de Besançon

    Besançon, 25030
    France

    Site Not Available

  • CHRU Morvan

    Brest, 29609
    France

    Active - Recruiting

  • CHU d'Estaing

    Clermont-Ferrand, 63003
    France

    Active - Recruiting

  • Hôpital Bicêtre

    Le Kremlin-Bicêtre, 94270
    France

    Active - Recruiting

  • Hôpital Jeanne de Flandre

    Lille, 59037
    France

    Active - Recruiting

  • Hôpital de la Timone-Enfants

    Marseille, 13005
    France

    Active - Recruiting

  • CHU Gui de Chautiac

    Montpeliier, 34295
    France

    Active - Recruiting

  • Hôpital Necker-Enfants malades

    Paris, 75749
    France

    Active - Recruiting

  • Centre Hospitalier Saint Nazaire

    Saint-Nazaire, 44600
    France

    Site Not Available

  • CHU Toulouse

    Toulouse, 31100
    France

    Active - Recruiting

  • Hôpital Clocheville

    Tours, 37000
    France

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.